Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Share Price History
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Mankind Pharma Ltd.
NSE: MANKIND
|
BSE: 543904
|
ISIN: INE634S01028
|
Industry: Pharmaceuticals
|
Expensive Rocket
2610.2000
-50.40
(
-1.89
%)
NSE
Sep 22, 2025
13:22 PM
Volume:
216.8K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Mankind Pharma Ltd.
12 Mar 2025
2610.20
-1.89%
Mankind Pharma Launches Generic Version Of Empagliflozin Diabetes Medication
NDTV Profit
The launch follows the expiration of Boehringer Ingelheim's patent for Empagliflozin in India.
Mankind Pharma Ltd. has an
average target
of 2840.50 from 2 brokers.
More from Mankind Pharma Ltd.
Recommended
Market trades lower, DEE Development approves Rs 300 crore fundraise
Trendlyne Marketwatch |
22 Sep 2025, 01:04PM
Five Interesting Stocks Today - September 19, 2025
The Baseline |
19 Sep 2025
Bull run fizzles out: Multibagger count in Indian equities falls
The Baseline |
18 Sep 2025